Physician
Obstetrics & Gynecology
Dr. Anil K. Sood, MD
|
|
Give Review
Anil Sood practices Obstetrics & Gynecology. He went to University of North Carolina at Chapel Hill School of Medicine. University of North Carolina at Chapel Hill School of Medicine is a one of the best medicals schools. University of North Carolina at Chapel Hill School of Medicine is ranked 22 in research and 2 in primary care medicine He has 6 awards "America's Top Doctors", "Top Doctors:SE Texas", "America's Top Doctors for Cancer", "Elected Member", "Fellow (FACOG)" and "Fellow (FACS)". Anil Sood is also published. He has 104 publications published. The lastest publication: "Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer.' Anil Sood accepts Medicare payments and is listed with Medicare.gov.
Publications
- Targeting the tumour microenvironment in ovarian Cancer.
- Immunological and pleiotropic effects of individual β-blockers and their relevance in Cancer therapies.
- Differentiation therapy for hepatocellular carcinoma: Multifaceted effects of miR-148a on tumor growth and phenotype and liver fibrosis.
- Complement Component 3 Is Regulated by TWIST1 and Mediates Epithelial-Mesenchymal Transition.
- Carcinoma of the Bartholin Gland: A Review of 33 Cases.
- miRNA Deregulation in Cancer Cells and the Tumor Microenvironment.
- SnapShot: Stress and Disease.
- Biobehavioral and neuroendocrine correlates of antioxidant enzyme activity in Ovarian carcinoma.
- Erythropoietin Stimulates Tumor Growth via EphB4.
- Adrenergic stimulation of DUSP1 impairs chemotherapy response in ovarian Cancer.
- Electron cryotomography reveals ultrastructure alterations in platelets from patients with ovarian Cancer.
- Dual metronomic chemotherapy with nab-paclitaxel and topotecan has potent anti-angiogenic activity in ovarian Cancer.
- Rethinking ovarian Cancer II: reducing mortality from high-grade serous ovarian Cancer.
- Sustained adrenergic signaling leads to increased metastasis in ovarian Cancer via increased PGE2 synthesis.
- Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian Cancer.
- A framework for a personalized surgical approach to ovarian Cancer.
- Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis.
- Diurnal cortisol and survival in epithelial ovarian Cancer.
- Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian Cancer.
- Preclinical and clinical development of siRNA-based therapeutics.
- New ways to successfully target tumor vasculature in ovarian Cancer.
- Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer.
- Anti-vascular therapies in ovarian Cancer: moving beyond anti-VEGF approaches.
- Survival outcome of stage I Ovarian clear cell carcinoma with lympho-vascular space invasion.
- Mind-body practices in Cancer care.
- Differential platelet levels affect response to taxane-based therapy in ovarian Cancer.
- Exosomes: A role for naturally occurring nanovesicles in Cancer growth, diagnosis and treatment.
- Copy Number Gain of hsa-miR-569 at 3q26.2 Leads to Loss of TP53INP1 and Aggressiveness of Epithelial Cancers.
- Molecular Pathways: Translational and Therapeutic Implications of the Notch Signaling Pathway in Cancer.
- Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian Cancer.
- Convergence of Nanotechnology and Cancer Prevention: Are We There Yet?
- Therapeutic Silencing of KRAS using Systemically Delivered siRNAs.
- Clinical Significance of CTNNB1 Mutation and Wnt Pathway Activation in Endometrioid Endometrial Carcinoma.
- The RNA-Binding Protein DDX1 Promotes Primary MicroRNA Maturation and Inhibits Ovarian Tumor Progression.
- MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian Cancer.
- Bisphosphonates Inhibit Stellate Cell Activity and Enhance Antitumor Effects of Nanoparticle Albumin Bound-Paclitaxel in Pancreatic Ductal Adenocarcinoma.
- Hematogenous metastasis of ovarian Cancer: rethinking mode of spread.
- Geometrical confinement of Gd(DOTA) molecules within mesoporous silicon nanoconstructs for MR imaging of Cancer.
- Definition of PKC-α, CDK6 and MET as therapeutic targets in triple-negative breast Cancer.
- miR-34a blocks Osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2.
- RNAi Therapies: Drugging the Undruggable.
- Platelet effects on ovarian Cancer.
- Effect of lymphovascular space invasion on survival of stage I epithelial ovarian Cancer.
- miR-101 suppresses the epithelial-to-mesenchymal transition by targeting ZEB1 and ZEB2 in Ovarian carcinoma.
- Clodronate inhibits tumor angiogenesis in mouse models of ovarian Cancer.
- MOLECULAR BIOMARKERS OF RESIDUAL DISEASE AFTER SURGICAL DEBULKING OF HIGH-GRADE SEROUS OVARIAN Cancer.
- Dynamin 2 along with microRNA-199a reciprocally regulate hypoxia-inducible factors and ovarian Cancer metastasis.
- Platelets and Cancer: a casual or causal relationship: revisited.
- Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, Fallopian t...
- Metronomic docetaxel in PRINT(R) nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian Cancer.
- Notch3 Pathway Alterations in Ovarian Cancer.
- Antagonism of Tumoral Prolactin Receptor Promotes Autophagy-Related Cell Death.
- Focal adhesion kinase: An alternative focus for anti-angiogenesis therapy in ovarian Cancer.
- Autocrine Effects of Tumor-Derived Complement.
- Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous Ovarian carcinoma.
- MiR-506 Suppresses Proliferation and Induces Senescence by Directly Targeting the CDK4/6-FOXM1 Axis in Ovarian Cancer.
- Monocyte subpopulations in angiogenesis.
- Activation of YAP1 Is Associated with Poor Prognosis and Response to Taxanes in Ovarian Cancer.
- Crosstalk between EphA2 and BRaf/CRaf is a Key Determinant of Response to Dasatinib.
- Perioperative beta-blocker use and survival in lung Cancer patients.
- Delivery of negatively charged liposomes into the atherosclerotic plaque of apolipoprotein E-deficient mouse aortic tissue.
- EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian Cancer.
- Liposomal siRNA nanocarriers for Cancer therapy.
- Role of Focal Adhesion Kinase in Regulating YB-1-Mediated Paclitaxel Resistance in Ovarian Cancer.
- Platelet-derived Growth Factor Receptor Alpha (PDGFRα) Targeting and Relevant Biomarkers in Ovarian Carcinoma.
- Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung Cancer.
- Non-Cancer life stressors contribute to impaired quality of life in ovarian Cancer patients.
- A novel non-coding RNA lncRNA-JADE connects DNA damage signalling to histone H4 acetylation.
- Poor survival with wild-type TP53 ovarian Cancer?
- Tumour angiogenesis regulation by the miR-200 family.
- Impact of cardiovascular comorbidity on ovarian Cancer mortality.
- Therapeutic Synergy between microRNA and siRNA in Ovarian Cancer Treatment.
- Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies.
- β-blockers: a new role in Cancer chemotherapy?
- Neighborhood matters: Response to EZH2 methyltransferase inhibitors.
- CA-125 Level as a Prognostic Indicator in Type I and Type II Epithelial Ovarian Cancer.
- Sleep disturbance, distress, and quality of life in ovarian Cancer patients during the first year after diagnosis.
- Biologic effects of dopamine on tumor vasculature in Ovarian carcinoma.
- Biological significance of HORM-A domain containing protein 1 (HORMAD1) in epithelial Ovarian carcinoma.
- Interleukin-1? Promotes Ovarian Tumorigenesis through a p53/NF-?B-Mediated Inflammatory Response in Stromal Fibroblasts.
- Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells.
- Enhancing Chemotherapy Response with Sustained EphA2 Silencing Using Multistage Vector Delivery.
- Cortisol and inflammatory processes in ovarian Cancer patients following primary treatment: Relationships with depression, fatigue, and disability.
- Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer.
- Latest research and treatment of advanced-stage epithelial ovarian Cancer.
- TARDBP regulates glycolysis in hepatocellular carcinomaby regulating PFKP through miR-520.
- Overexpression of enhancer of zeste homolog 2 (EZH2) and focal adhesion kinase (FAK) in high grade endometrial carcinoma.
- Integrated Analyses Identify a Master MicroRNA Regulatory Network for the Mesenchymal Subtype in Serous Ovarian Cancer.
- Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian Cancer.
- Src activation by ?-adrenoreceptors is a key switch for tumour metastasis.
- A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, Fallopian tube and primary peritoneal carcinomas: A Gynecologic Oncol...
- Adrenergic signaling and Cancer: Deciphering the connections.
- Importance of adrenergic pathways in women's Cancers.
- Correction: Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast Cancer.
- Contemporary use of bevacizumab in ovarian Cancer.
- Epigenetic analysis of the Notch superfamily in high-grade serous ovarian Cancer.
- Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies.
- Highly Specific Targeting of the TMPRSS2/ERG Fusion Gene Using Liposomal Nanovectors.
- FOXM1 mediates Dox resistance in breast Cancer by enhancing DNA repair.
- Significance of lymphovascular space invasion in epithelial ovarian Cancer.
- Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian Cancer.
- Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth.
- Characteristics of 10-year survivors of high-grade serous Ovarian carcinoma.
Schools
Univ Of Nc Chapel Hill Sch Of Med
University Fl
University Ia
Procedures Preformed
- Colposcopy
- Destruction or Excision of Vaginal Lesions
- Gynecologic Cancer Screening
- Hysterectomy - Open
- View All
Conditions Treated
- Asymptomatic Post-Menopausal Status
- Atrophic Vaginitis
- Cervical Cancer
- Chronic Pelvic Pain
- View All
Doctors Specialties
- Gynecologic Oncology
- Obstetrics
- Gynecology
Accepted Insurances
Awards
- America's Top Doctors
- Top Doctors:SE Texas
- America's Top Doctors for Cancer
- Elected Member
- Fellow (FACOG)
- Fellow (FACS)
Education
-
University of Florida -
University of North Carolina at Chapel Hill School of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1184720906 | |
| NPPES Provider LastName | SOOD | |
| NPPES Provider FirstName | ANIL | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Gynecological/Oncology | |
| Total Claim Count | 43.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 11.0 | |
| Percent Opioid Claims | 25.58 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1184720906 |
| Last Name Of The Provider | SOOD |
| First Name Of The Provider | ANIL |
| View All |
Similar Doctors
|
Dr. Nicolas P. Xydas, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Richard D. Drake, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. John L. Dalrymple, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Chuong H. Pham, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gary L. Binder, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Concepcion R. Diaz-Arrastia, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aparna A. Kamat, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer K. Burzawa, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert H. Barr Sr., MD |
|
|
Dr. Gordon B. Mills, MD
This Doctor is OpenDoctor Recommended.
|